Repare Therapeutics Future Growth
Future criteria checks 0/6
Repare Therapeutics's revenue and earnings are forecast to decline at 3.3% and 19% per annum respectively. EPS is expected to decline by 9.9% per annum. Return on equity is forecast to be -54.7% in 3 years.
Key information
-19.0%
Earnings growth rate
-9.9%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | -3.3% |
| Future return on equity | -54.7% |
| Analyst coverage | Good |
| Last updated | 16 Dec 2024 |
Recent future growth updates
Recent updates
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher
Nov 13
There's No Escaping Repare Therapeutics Inc.'s (NASDAQ:RPTX) Muted Revenues Despite A 35% Share Price Rise
Oct 05Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 9 | -180 | -69 | -54 | 2 |
| 12/31/2026 | 19 | -155 | -92 | -87 | 6 |
| 12/31/2025 | 7 | -149 | -95 | -94 | 7 |
| 12/31/2024 | 56 | -91 | -62 | -62 | 8 |
| 9/30/2024 | 67 | -84 | -78 | -77 | N/A |
| 6/30/2024 | 69 | -69 | -80 | -80 | N/A |
| 3/31/2024 | 98 | -46 | -85 | -83 | N/A |
| 12/31/2023 | 51 | -94 | -129 | -127 | N/A |
| 9/30/2023 | 56 | -97 | -128 | -129 | N/A |
| 6/30/2023 | 167 | -3 | -8 | -8 | N/A |
| 3/31/2023 | 137 | -29 | -2 | -1 | N/A |
| 12/31/2022 | 132 | -29 | 0 | 0 | N/A |
| 9/30/2022 | 121 | -26 | 7 | 9 | N/A |
| 6/30/2022 | 8 | -132 | -114 | -112 | N/A |
| 3/31/2022 | 8 | -120 | -103 | -102 | N/A |
| 12/31/2021 | 8 | -107 | -87 | -86 | N/A |
| 9/30/2021 | 1 | -94 | -81 | -78 | N/A |
| 6/30/2021 | 1 | -77 | -69 | -65 | N/A |
| 3/31/2021 | 0 | -62 | -14 | -11 | N/A |
| 12/31/2020 | 0 | -53 | -8 | -6 | N/A |
| 9/30/2020 | N/A | -46 | -4 | -2 | N/A |
| 6/30/2020 | N/A | -40 | 11 | 12 | N/A |
| 3/31/2020 | N/A | -35 | -32 | -31 | N/A |
| 12/31/2019 | N/A | -27 | -20 | -18 | N/A |
| 12/31/2018 | N/A | -14 | -13 | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RPTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RPTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RPTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RPTX's revenue is expected to decline over the next 3 years (-3.3% per year).
High Growth Revenue: RPTX's revenue is forecast to decline over the next 3 years (-3.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RPTX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 23:11 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Repare Therapeutics Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Timothy Chiang | Capital One Securities, Inc. |
| Chris Shibutani | Goldman Sachs |